| # | Country | Total Patents | |
|---|---|---|---|
| #1 | EPO (European Patent Office) | 11 | |
| #2 | China | 10 | |
| #3 | Argentina | 9 | |
| #4 | Canada | 9 | |
| #5 | Japan | 9 | |
| #6 | United States | 9 | |
| #7 | Republic of Korea | 8 | |
| #8 | Mexico | 8 | |
| #9 | New Zealand | 8 | |
| #10 | WIPO (World Intellectual Property Organization) | 8 | |
| #11 | Poland | 7 | |
| #12 | Brazil | 6 | |
| #13 | Israel | 6 | |
| #14 | Norway | 6 | |
| #15 | South Africa | 4 | |
| #16 | Costa Rica | 3 | |
| #17 | Australia | 2 | |
| #18 | Hong Kong | 2 | |
| #19 | Morocco | 2 | |
| #20 | Ukraine | 2 | |
| #21 | Chile | 1 | |
| #22 | EAPO (Eurasian Patent Organization) | 1 | |
| #23 | Ecuador | 1 | |
| #24 | Hungary | 1 | |
| #25 | Montenegro | 1 | |
| #26 | Peru | 1 | |
| #27 | Singapore | 1 | |
| #28 | Tunisia | 1 | |
| #29 | Taiwan | 1 |
| # | Industry | |
|---|---|---|
| #1 | Biotechnology | |
| #2 | Pharmaceuticals | |
| #3 | Foods and drinks | |
| #4 | Machines | |
| #5 | Environmental technology | |
| #6 | Measurement |
| # | Technology | |
|---|---|---|
| #1 | Peptides | |
| #2 | Therapeutic chemical compounds | |
| #3 | Medical preparations | |
| #4 | Microorganisms | |
| #5 | Fermentation | |
| #6 | Enzymes | |
| #7 | Unspecified technologies | |
| #8 | Climate change mitigation in goods production | |
| #9 | Analysing materials |
| # | Name | Total Patents |
|---|---|---|
| #1 | Umana Pablo | 99 |
| #2 | Mossner Ekkehard | 37 |
| #3 | Suter Tobias | 33 |
| #4 | Ferrara Claudia | 32 |
| #5 | Bruenker Peter | 28 |
| #6 | Bailey James E | 18 |
| #7 | Moessner Ekkehard | 16 |
| #8 | Jean-Mairet Joel | 14 |
| #9 | Brunker Peter | 13 |
| #10 | Puentener Ursula | 10 |
| Publication | Filing date | Title |
|---|---|---|
| MX2007013924A | Antigen binding molecules having modified fc regions and altered binding to fc receptors. | |
| US2006223096A1 | Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function | |
| EP2404937A1 | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof | |
| CN1761746A | Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function | |
| MXPA04001072A | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity. | |
| EP1071700A1 | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |